Altrinsic Global Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Altrinsic Global Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-168,800	Closed	-$2.75M	–	74
2021 Q4	$2.75M	Hold	168,800	–	–	0.09%	53
2021 Q3	$2.51M	Hold	168,800	–	–	0.08%	61
2021 Q2	$3.37M	Hold	168,800	–	–	0.1%	55
2021 Q1	$3.9M	Sell	168,800 -146,430	-46%	-$4.08M	0.12%	54
2020 Q4	$7.79M	Buy	315,230 +28,155	+10%	+$933K	0.26%	45
2020 Q3	$11.9M	Buy	287,075 +7,133	+3%	+$328K	0.49%	38
2020 Q2	$13.4M	Sell	279,942 -5,697	-2%	-$440K	0.58%	34
2020 Q1	$18M	Sell	285,639 -5,092	-2%	-$458K	0.99%	30
2019 Q4	$36M	Sell	290,731 -17,097	-6%	-$1.53M	1.51%	21
2019 Q3	$20.4M	Buy	307,828 +25,474	+9%	+$1.71M	0.88%	30
2019 Q2	$22.5M	Buy	282,354 +1,450	+0.5%	+$130K	1.04%	26
2019 Q1	$31.4M	Buy	280,904 +2,960	+1%	+$323K	1.45%	19
2018 Q4	$28M	Sell	277,944 -34,683	-11%	-$3.6M	1.34%	26
2018 Q3	$39.5M	Sell	312,627 -70,539	-18%	-$7.46M	1.79%	18
2018 Q2	$32.2M	Buy	383,166 +7,943	+2%	+$582K	1.27%	29
2018 Q1	$23.1M	Buy	375,223 +64,923	+21%	+$3.91M	0.93%	33
2017 Q4	$18.1M	Buy	310,300 +77,756	+33%	+$4.9M	0.7%	40
2017 Q3	$13.5M	Buy	232,544 +66,521	+40%	+$7.17M	0.51%	43
2017 Q2	$20.1M	Sell	166,023 -27,346	-14%	-$3.17M	0.73%	42
2017 Q1	$21.9M	Buy	193,369 +4,465	+2%	+$521K	0.74%	42
2016 Q4	$20.5M	Sell	188,904 -26,848	-12%	-$3.2M	0.76%	41
2016 Q3	$35.5M	Sell	215,752 -68,478	-24%	-$10.8M	1.3%	26
2016 Q2	$40.6M	Sell	284,230 -8,457	-3%	-$1.23M	1.15%	29
2016 Q1	$37.6M	Buy	292,687 +115,870	+66%	+$13.7M	1.05%	36
2015 Q4	$26.4M	Sell	176,817 -7,871	-4%	-$1.33M	0.69%	45
2015 Q3	$30.6M	Sell	184,688 -5,982	-3%	-$1.32M	0.71%	43
2015 Q2	$46M	Sell	190,670 -48,090	-20%	-$12.8M	0.94%	38
2015 Q1	$67.3M	Sell	238,760 -63,009	-21%	-$13.6M	1.46%	28
2014 Q4	$47.1M	Buy	301,769 +250,969	+494%	+$46.4M	0.97%	36
2014 Q3	$12M	Hold	50,800	–	–	0.23%	50
2014 Q2	$12M	Hold	50,800	–	–	0.21%	50
2014 Q1	$16.8M	Hold	50,800	–	–	0.29%	48
2013 Q4	$3.47M	Buy	50,800 +25,800	+103%	+$1.49M	0.06%	68
2013 Q3	$1.73M	Buy	+25,000	New	+$1.23M	0.03%	73

Other funds holding ICPT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Altrinsic Global Advisors's ICPT Position: Q1 2022 in Review

Altrinsic Global Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2022, closing a stake of 168,800 shares — an estimated $2.75M sold.

Altrinsic Global Advisors first reported a position in ICPT in Q3 2013 and held it in 34 quarters. The position peaked at $67.3M in Q1 2015. 148 funds tracked by Wall St. Rank hold ICPT as of Q1 2022.

Altrinsic Global Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
Altrinsic Global Advisors sold 168,800 Intercept Pharmaceuticals, Inc. shares in Q1 2022, an estimated $2.75M.
Altrinsic Global Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2013 and held it in 34 quarters.
Altrinsic Global Advisors's Intercept Pharmaceuticals, Inc. position peaked at $67.3M in Q1 2015.
148 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2022.

Based on Altrinsic Global Advisors's 13F filing for Q1 2022, filed 16 May 2022.